Using nanoparticles to enhance immune response against aggressive cancers
Dual action immunostimulatory nanoparticles for treatment of aggressive cancers
This study is testing a new way to help your immune system fight cancer by using tiny particles that boost immune cells right in the tumor, making it easier for your body to recognize and attack the cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11092920 on NIH RePORTER |
What this research studies
This research investigates a novel approach to cancer treatment by utilizing dual action immunostimulatory nanoparticles that aim to enhance the immune system's ability to recognize and destroy tumor cells. The nanoparticles are designed to target and activate dysfunctional immune cells within the tumor microenvironment, which often suppresses effective immune responses. By delivering specific molecules that block immune checkpoints and stimulate immune activity, this approach seeks to reprogram the tumor environment to support a stronger anti-cancer immune response. Patients may receive these nanoparticles directly into their tumors as part of the treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with aggressive cancers who have shown resistance to current immunotherapy treatments.
Not a fit: Patients with non-aggressive cancers or those who are not eligible for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for aggressive cancers, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Other research has shown promising results using similar nanoparticle approaches to enhance immune responses in cancer treatment, indicating potential for success in this novel application.
Where this research is happening
Cleveland, United States
- Case Western Reserve University — Cleveland, United States (Active)
Researchers
- Principal investigator: Karathanasis, Efstathios — Case Western Reserve University
- Study coordinator: Karathanasis, Efstathios
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.